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Objectives: To analyze the relationship between in vitro fertilization (IVF) pregnancy rate and basal serum
hormone levels before patients begin an IVF course.
Materials and methods: In this retrospective study, we analyzed patients with anti-Müllerian hormone
(AMH) data and IVF data from January 2009 to October 2012. Pregnancy rates were calculated by AMH
and follicle stimulating hormone quartiles and analyzed using the independent samples t test.
Furthermore, patients were divided into three groups by age. The Chi-square test was used to assess the
association between the parameters and IVF pregnancy rates.
Results: From the 910 IVF treatment courses, 377 (41.4%) clinical pregnancies resulted. The pregnant and
nonpregnant groups differed signiﬁcantly in age and FSH and AMH levels. The pregnancy rate was 53.3%
for patients aged <32 years and 22.1% for patients aged >38 years. The pregnancy rate was 53.4% for
patients with FSH levels <5.6 mIU/mL and 25.8% for patients with FSH levels >8.9 mIU/mL. The preg-
nancy rate was 56.8% for patients with AMH levels >4.0 ng/mL and 20.0% for patients with AMH levels
<1.1 ng/mL. Furthermore, among patients aged <40 years, AMH and FSH were signiﬁcantly associated
with pregnancy rate. Higher pregnancy rates were found among the groups with higher AMH levels than
in groups with lower AMH levels.
Conclusion: For patients aged <40 years, basal serum AMH level and FSH level affected the IVF pregnancy
rate, and patients with higher AMH levels had better pregnancy rates.
Copyright © 2014, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All
rights reserved.Introduction
Treatment for sterility entered a new era after the ﬁrst baby
conceived by in vitro fertilization (IVF) was born in 1978 [1]. The
rush to control the female reproductive cycle created the devel-
opment of reproductive medicine and assisted reproductive tech-
nology, based on academic reproductive endocrinology [2].
The female menstrual cycle is regulated by a series of hormones,
including gonadotropin-releasing hormone, follicle stimulating
hormone (FSH), luteinizing hormone (LH), estradiol (E2), and pro-
gesterone. Estrogen and progesterone regulate follicle growth fromnd Gynecology, Linkou Chang
nship, Taoyuan County 333,
ang).
bstetrics & Gynecology. Publishedthe start of follicle development through regulation of the corpus
luteum [3]. FSH plays a role in primordial follicle survival [4]. When
the dominant follicles appear, there is a transformation of de-
pendency from FSH to LH. Through altering LH receptor mRNA
expression, LH-responsiveness of theca and granulosa cells during
follicular development changes. Furthermore, the LH surge triggers
ovulation. The interactions between extraovarian and intraovarian
factors determine the fate of the follicle and the quality of the
oocyte [5].
Intervention in the menstrual cycle by induction of the events
leading to egg production and possible fertilization upon intro-
duction of sperm, IVF, is costly to women in terms of physiological
and psychological distress, not to mention the ﬁnancial costs of
resources required to complete IVF [6]. Except for multiple gesta-
tions in one pregnancy, the side effects of IVF include complications
of surgery and ascites due to ovarian hyperstimulation syndromeby Elsevier Taiwan LLC. All rights reserved.
Table 1
Patient characteristics in pregnant and nonpregnant patients.
Nonpregnant (n ¼ 533) Pregnant (n ¼ 377) p*
Age (y) 36.2 ± 4.7 34.0 ± 3.9 <0.001
FSH (mIU/mL) 8.7 ± 5.3 6.9 ± 2.6 <0.001
LH (mIU/mL) 5.2 ± 3.7 5.1 ± 3.7 0.435
E2 (pg/mL) 37.7 ± 22.5 38.2 ± 31.3 0.228
AMH (ng/mL) 2.6 ± 3.1 3.9 ± 3.6 <0.001
*p < 0.05 is considered statistically signiﬁcant.
AMH¼ anti-Müllerian hormone; E2 ¼ serum estradiol during the follicular phase of
menses; FSH ¼ follicle stimulating hormone; LH ¼ luteinizing hormone.
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prognostic factors predictive of IVF pregnancy success before pa-
tients begin an IVF course.
Anti-Müllerian hormone (AMH), produced by granulosa cells of
preantral follicles, restricts folliculogenesis by an inhibitory effect
on FSH sensitivity [8]. As a result, AMH is considered a marker for
assessing ovarian reserve [9]. Clinically, AMH is used as the pre-
dictive factor for ovarian response and IVF pregnancy rate. Many
published papers discuss AMH as the predictive factor for IVF
pregnancy success and ovarian hyperstimulation syndrome.
Nonetheless, the predictive results for AMH are inconclusive
[10,11].
The purpose of this retrospective study was to assess the rela-
tionship between IVF pregnancy rate and AMH level. We also
analyzed the relationships between IVF pregnancy rate and basal
serum hormone levels (FSH, LH, and E2) before patients began an
IVF course.
Materials and methods
The IVF treatment course records of 1003 patients with AMH
data were retrieved from the Department of Obstetrics and Gyne-
cology, Chang Gung University College of Medicine, Linkou Medical
Center, Taoyuan, Taiwan from January 2009 to October 2012.
Ninety-three (9.27%) treatment courses without embryo transfer,
unrelated to ovarian reserve and embryo quality, were excluded
from this study. Four (0.40%) treatment courses were from oocyte
donors. No sperm was found after microsurgical epididymis sperm
aspiration or testicular sperm aspiration in six (0.60%) treatment
courses. There were 20 (1.99%) treatment courses for preimplan-
tation genetic diagnosis, with genetically abnormal embryos for
embryo transfer. Three (0.30%) patients dropped out due to indi-
vidual problems. All of these IVF courses were excluded. Another 56
(5.58%) patients requested oocyte or embryo cryopreservation.
Severe ovarian hyperstimulation occurred in three patients (0.30%).
One patient (0.10%) had internal bleeding after oocyte retrieval.
These IVF courses were also excluded.
To consider the effect of ovarian function, we included other
treatment courses in which there was little ovarian response, no
oocyte retrieved, no fertilized embryo, poor embryo quality, or
arrested embryo development during culture. As a result, 910 IVF
treatment courses were included, and all embryo transfers, when
done, were fresh.Table 2
Pregnancy rates by age, follicle stimulating hormone (FSH), and anti-Müllerian hormone
Quartile <25% 25e50%
Range Pregnancy rate (%) Range Pregnancy ra
Age (y)* <32 (n ¼ 182) 53.3 32e35 (n ¼ 224) 49.6%
FSH (mIU/mL)* <5.6 (n ¼ 221) 53.4 5.6e7.1 (n ¼ 220) 45.5%
AMH (ng/mL)* <1.1 (n ¼ 230) 20.0 1.1e2.2 (n ¼ 230) 40.9%
*p < 0.001.Serum samples were collected during the follicular phase of the
menstrual cycle. FSH, LH, E2, and AMH were measured in all
patients.
AMH levels were measured using a two-step immunological
sandwich type assay for the in vitro determination of AMH/Mülle-
rian inhibiting substance in human serum and plasma (IMMUNO-
TECH, Beckman Coulter, Marseille, France). The lowest AMH
concentration signiﬁcantly different from the zero calibrator was
0.14 ng/mL. The intra-assay and interassay coefﬁcients of variation
were 12.3% and 14.2%, respectively. The measurement range of
AMH was 0.14e21 ng/mL.
The deﬁnition of pregnancy in this study was clinical pregnancy,
with ultrasound proof of one or more intrauterine gestational sacs.
This study was approved by the Research Ethics Committee of
Chang Gung Memorial Hospital, Taoyuan County, Taiwan (Institu-
tional Review Board No.101-4814B). The need for informed consent
was waived due to the retrospective nature of the study.
Statistical analysis
Data are presented as mean ± standard deviation and percent-
age. The independent samples t test was used to compare the
statistical relationships of all parameters between the pregnancy
and nonpregnancy groups. The pregnancy rate was calculated by
quartiles of the statistically signiﬁcant AMH and FSH levels.
Furthermore, patients were divided into three groups by age, and
the Chi-square test was used to assess the relationship between
pregnancy rate and AMH and FSH levels. SPSS version 16.0 (SPSS
Inc., Chicago, IL, USA) was used for all statistical analyses. A p value
<0.05 was considered statistically signiﬁcant.
Results
From the 910 IVF courses, 377 (41.4%) clinical pregnancies
resulted. The mean age in the pregnant group was 34.0 ± 3.9 years
and 36.2 ± 4.7 years in the non-pregnant group. FSH was
6.9 ± 2.6 mIU/mL and 8.7 ± 5.3 mIU/mL whereas AMH was
3.9 ± 3.6 ng/mL and 2.6 ± 3.1 ng/mL in the pregnant and
nonpregnant groups, respectively. Age and FSH and AMH levels
differed signiﬁcantly between the pregnant and nonpregnant
groups (Table 1). Compared with the nonpregnant group, patients
in the pregnant groupwere younger, and had a lower FSH level, and
a higher AMH level.
When pregnancy data were analyzed by age quartiles, the
pregnancy rate ranged from 53.3% in the age <32 years group to
22.1% in the >38 years group (p < 0.001). Similarly, in the group
with AMH >4.0 ng/mL, the pregnancy rate was 56.8% whereas it
was 20.0% in the group with AMH <1.1 ng/mL (p < 0.001; Table 2).
Comparably, the pregnancy rate ranged from 53.4% in the group
with FSH <5.6 mIU/mL to 25.8% in the groupwith FSH >8.9 mIU/mL
(p < 0.001; Table 2).
Patients were divided into three groups by age: <35 years
(n ¼ 406); 35e40 years (n ¼ 345); and >40 years (n ¼ 159). Pa-
tients aged <35 years with AMH >4.0 ng/mL had a pregnancy rate
of 60.4% whereas the pregnancy rate was 28.1% in the group with(AMH) quartiles.
50e75% >75%
te (%) Range Pregnancy rate (%) Range Pregnancy rate (%)
35e38 (n ¼ 223) 48.0 >38 (n ¼ 281) 22.1
7.1e8.9 (n ¼ 236) 41.9 >8.9 (n ¼ 233) 25.8
2.2e4.0 (n ¼ 221) 48.4 >4.0 (n ¼ 229) 56.8
Table 3
Pregnancy rates by anti-Müllerian hormone (AMH) level among different age groups.
Age (y) AMH range
(ng/mL)
Pregnancy
rate (%)
AMH range
(ng/mL)
Pregnancy
rate (%)
AMH range
(ng/mL)
Pregnancy
rate (%)
AMH range
(ng/mL)
Pregnancy
rate (%)
<35* <1.1 (n ¼ 57) 28.1 1.1e2.2 (n ¼ 106) 48.1 2.2e4.0 (n ¼ 109) 55.0 >4.0 (n ¼ 134) 60.4
35e40* <1.1 (n ¼ 102) 19.6 1.1e2.2 (n ¼ 80) 41.3 2.2e4.0 (n ¼ 83) 48.2 >4.0 (n ¼ 80) 58.8
>40** <1.1 (n ¼ 71) 14.1 1.1e2.2 (n ¼ 44) 22.7 2.2e4.0 (n ¼ 29) 24.1 >4.0 (n ¼ 15) 13.3
*p < 0.001.
**p < 0.506.
Table 4
Pregnancy rates by follicle stimulating hormone (FSH) among different age groups.
Age (y) FSH range
(mIU/mL)
Pregnancy
rate (%)
FSH range
(mIU/mL)
Pregnancy
rate (%)
FSH range
(mIU/mL)
Pregnancy
rate (%)
FSH range
(mIU/mL)
Pregnancy
rate (%)
<35* <5.6 (n ¼ 119) 57.1 5.6e7.1 (n ¼ 113) 49.6 7.1e8.9 (n ¼ 94) 57.4 >8.9 (n ¼ 80) 37.5
35e40** <5.6 (n ¼ 77) 59.7 5.6e7.1 (n ¼ 78) 46.2 7.1e8.9 (n ¼ 98) 35.7 >8.9 (n ¼ 92) 25.0
>40*** <5.6 (n ¼ 25) 16.0 5.6e7.1 (n ¼ 29) 27.6 7.1e8.9 (n ¼ 44) 22.7 >8.9 (n ¼ 61) 11.5
*p < 0.026.
**p < 0.001.
***p < 0.236.
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group, pregnancy rates ranged from 58.8% for patients with AMH
>4.0 ng/mL to 19.6% in the group with AMH <1.1 ng/mL
(p < 0.001). The pregnancy rate of patients aged >40 years ranged
from 13.3% to 24.1%, depending on the AMH level (p ¼ 0.506;
Table 3).
Patients aged <35 years with FSH levels of <5.6 mIU/mL had a
pregnancy rate of 57.1% whereas the pregnancy rate was 37.5% in
the group with FSH >8.9 mIU/mL (p¼ 0.026; Table 4). Patients aged
35e40 years with FSH levels <5.6 mIU/mL had a pregnancy rate of
59.7% whereas the pregnancy rate was 25.0% in the group with FSH
levels >8.9 mIU/mL (p < 0.001; Table 4). Patients aged >40 years
had pregnancy rates ranging from 27.6% to 11.5% depending on the
FSH level (p ¼ 0.236; Table 4).
Discussion
Prediction of IVF pregnancy rates using serum AMH levels is a
controversial issue. Some authors concluded that AMH levels are
associated with pregnancy rates [10,12e14] whereas others
concluded that they are not [11,15e18]. In our study, based on 377
clinical pregnancies, the mean age in the pregnant group was
34.0 ± 3.9 years, FSH was 6.9 ± 2.6 mIU/mL, LH was 5.1 ± 3.7 mIU/
mL, E2 was 38.2 ± 31.3 pg/mL, and AMH was 3.9 ± 3.6 ng/mL. The
age and FSH and AMH levels differed signiﬁcantly between the
pregnant and nonpregnant groups (Table 1). The patients aged
<32 years had a 53.3% pregnancy rate whereas the group aged
>38 years had a 22.1% pregnancy rate. Younger patient groups had
better pregnancy rates than older patient groups (Table 2). Among
the patient group with AMH >4.0 ng/mL, the pregnancy rate was
56.8%; it was 20.0% in the group with AMH <1.1 ng/mL (Table 2).
Higher pregnancy rates were found in the groups with greater AMH
levels. In the group with FSH <5.6 mIU/mL, the pregnancy rate was
53.4%; it was 25.8% in the group with FSH >8.9 mIU/mL (Table 2).
Higher pregnancy rates were found in the groups with lower FSH
levels.
Age inﬂuenced the relationship between AMH and IVF preg-
nancy outcome [19], so patients were divided into three groups by
age. Patients, aged <35 years with higher AMH levels had greater
pregnancy rates (60.4e28.1%) than older patients with lower AMH
levels. A similar pattern was found in the group aged 35e40 years
(pregnancy rate range, 58.8e19.6%). Among patients aged
>40 years, pregnancy rate did not differ signiﬁcantly based on AMHlevel (Table 3). Thus, AMH level could be used as a predictive factor
of IVF pregnancy rate for patients aged <40 years. Furthermore,
among patients aged <40 years, FSH levels also inﬂuenced IVF
pregnancy rates. Patients, with lower FSH levels typically had
higher pregnancy rates (Table 4), even though among patients
aged < 35 years, the group with FSH ¼ 7.1e8.9 mIU/mL had the
highest pregnancy rate. This could be due to variations of FSH
during the menstrual cycle. Similar to pregnancy rates associated
with AMH levels, pregnancy rates associated with FSH levels in
patients aged >40 years did not differ signiﬁcantly.
Based on our results, among patients aged >40 years, the uterus
played a more pivotal role than the ovaries did in inﬂuencing IVF
pregnancy rates. To conﬁrm this hypothesis, additional studies to
evaluate endometrial receptivity, such as endometrial morphology
by ultrasound [20], biomarkers by lipidomics [21], and genomic
signature by endometrial receptivity array [22] have yet to be
investigated.
The reduction in ovarian reserve is a physiological process
occurring in the late reproductive period, and it is consistently
associated with a decrease in AMH levels [23]. As a result, patients
with low AMH levels were urged to undergo IVF treatment as soon
as possible. Furthermore, for patients with low AMH levels, clini-
cians had to ﬁnd effective interventions to improve ovarian
response, such as dehydroepiandrosterone [24,25], transdermal
testosterone [26], and visfatin [27] treatments.
For patients with poor ovarian response, ovum donation is the
only proven method of achieving pregnancy in patients with pri-
mary ovarian insufﬁciency or premature ovarian failure [28].
Nonetheless, several of these patients became pregnant after cyclic
estrogen/progesterone [29e31], exogenous gonadotropin [32], and
gonadotropin-releasing hormone antagonist therapies [33], and
spontaneously [34,35]. More clinical trials are required to deter-
mine the best method to treat patients with primary ovarian
insufﬁciency or premature ovarian failure.
In conclusion, for patients aged <40 years, basal serum AMH
level and FSH level affected the IVF pregnancy rate, and patients
with higher AMH levels had higher pregnancy rates. To improve the
clinical beneﬁts of AMH, more interventions for patients with low
AMH levels need to be investigated.
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